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Pelationship Between B-Type
atriuretic Peptides and Pulmonary
apillary Wedge Pressure in the Intensive Care Unit
aul R. Forfia, MD, Stanley P. Watkins, MD, J. Eduardo Rame, MD, Kerry J. Stewart, EDD,
dward P. Shapiro, MD
altimore, Maryland
OBJECTIVES We examined whether B-type natriuretic peptides (BNP) can serve as noninvasive markers of
pulmonary capillary wedge pressure (PCWP) in the setting of critical illness.
BACKGROUND The BNP and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are highly correlated
with left ventricular (LV) filling pressures in patients with depressed LV systolic function.
However, their relationship to PCWP in a heterogeneous intensive care unit (ICU)
population has not been established.
METHODS We prospectively studied 40 patients in the ICU requiring invasive hemodynamic monitoring.
Hemodynamics were recorded simultaneously with blood sampling for BNP and NT-proBNP.
RESULTS The BNP (median 420 pg/ml) and NT-proBNP (median 3,304 pg/ml) levels were markedly
elevated, but weakly correlated with PCWP (BNP, r  0.40, NT-proBNP, r  0.32) and
other cardiac parameters. Peptide levels were approximately four-fold greater in patients with
impaired (estimated glomerular filtration rate [eGFR] 60 ml/min) versus normal (eGFR
60 ml/min) renal function, despite similar PCWP, cardiac index, and LV ejection fraction.
In addition, both BNP and NT-proBNP showed stronger correlations with PCWP in
patients with preserved (BNP, r  0.58, NT-proBNP, r  0.73) versus impaired renal
function (BNP, r  0.48, NT-proBNP, r  0.34). Interaction terms between eGFR and
BNP (p  0.06) and NT-proBNP (p  0.04) suggest that eGFR modulates the relationship
of these peptides to filling pressures.
CONCLUSIONS The BNPs are markedly elevated, yet show only weak correlations to PCWP in ICU patients
requiring invasive hemodynamic monitoring. Thus, a single value for BNP or NT-proBNP
may not be a clinically useful noninvasive marker of filling pressures in the critically ill patient.
This appears to be especially true in patients with impaired renal function. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.046Cardiol 2005;45:1667–71) © 2005 by the American College of Cardiology Foundation
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The B-type natriuretic peptide (BNP) and N-terminal
ro-B-type natriuretic peptide (NT-proBNP) are co-
ecreted from the cardiac ventricles in response to stretch
nd other non-mechanical stimuli (1,2). Both peptides are
arkers of left ventricular (LV) dysfunction, and elevated
evels aid in discriminating cardiac from non-cardiac dys-
nea (3). Peptide levels also correlate with LV filling
ressures in patients with depressed systolic function (4,5).
owever, it is unclear whether BNP or NT-proBNP are
arkers of pulmonary capillary wedge pressure (PCWP) in
population of critically ill patients with a broad range of
iagnoses and cardiac function.
We conducted a prospective observational study examin-
ng the relationship between BNP and NT-proBNP and
CWP in critically ill patients requiring invasive hemody-
amic monitoring. We sought to determine whether these
eptides can be used as noninvasive markers of pulmonary
ongestion in this cohort.
ETHODS
tudy population. Adult intensive care units (ICUs) were
creened for patients in whom a pulmonary artery catheter
From the Division of Cardiology, Johns Hopkins Hospital, Baltimore, Maryland.s
Manuscript received June 4, 2004; revised manuscript received October 7, 2004,
ccepted January 26, 2005.PAC) had been inserted for a clinical indication. Patients
ith an acute myocardial infarction, a troponin I level 1.0
g/ml, and those recovering from cardiac surgery or receiv-
ng nesiritide were excluded. Informed consent was ob-
ained. The study was approved by the Johns Hopkins
nstitutional Review Board.
emodynamics. Adequate position of the PAC was con-
rmed by radiograph and hemodynamic waveform analysis.
ll PAC-derived hemodynamics were recorded at end
xpiration, with PCWP adjusted for a positive end expira-
ory pressure 10 cm H2O (6). Cardiac output was mea-
ured by thermodilution in triplicate. An echocardiogram
as performed the same day as the study. Left ventricular
imensions, mass, wall stress, and left ventricular ejection
raction (LVEF) were measured as previously described (7).
Glomerular filtration rate was estimated using the
ethod of Cockcroft and Gault, incorporating ideal body
eight (8). An estimated glomerular filtration rate (eGFR)
60 ml/min defined impaired renal function (9).
lood sampling. Arterial blood was collected simultaneous
ith hemodynamic recordings and analyzed within 1 h. The
NP analysis was performed on whole blood using the
riage BNP assay (Biosite Inc., San Diego, California) (3).
he NT-proBNP analysis was performed on serum using a
tandard core laboratory assay (Roche Diagnostics, Basel,
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T-proBNP assays were reported as 5,000 and 70,000
g/ml, respectively. Samples run in duplicate (n  7) varied
y 1%, with a correlation coefficient of 0.99.
tatistical analysis. Values are expressed as the median and
nterquartile range (IQR). Differences between medians
ere detected by Wilcoxon rank-sum test with two-tailed p
alues of 0.05. Because the natriuretic peptide data were
ot normally distributed, log BNP and log NT-proBNP
ere used in the correlations and regression models. A
ultivariate linear regression model was used to ascertain
ndependent predictors of BNP and NT-proBNP. The
nteraction between BNP (and NT-proBNP) and eGFR on
he relationship to PCWP was tested in a regression model.
n interaction term was created by entering log BNP (and
og NT-proBNP) into the model as a continuous variable
nd eGFR as a binary variable, defined as normal (GFR
60 ml/min) or abnormal (GFR 60 ml/min). A p value
0.05 was considered significant. Statistical analyses were
erformed using Stata software version 8.0 (College Station,
exas).
ESULTS
opulation characteristics. Table 1 summarizes the base-
ine clinical characteristics and hemodynamics of this criti-
ally ill population. The median age was 62 years. Approx-
mately two-thirds of patients were intubated and
echanically ventilated. A similar proportion of patients
ad renal insufficiency (75% acute, 25% chronic). The
ajority of patients (68%) had preserved LV systolic func-
ion (LVEF 50%). Fourteen patients (35%) died while in
he hospital.
NPs and hemodynamics. The concentrations of BNP
median 420 pg/ml, IQR 197 to 1,740) and NT-proBNP
median 3,304 pg/ml, IQR 1,153 to 14,713) were markedly
levated. However, natriuretic peptide levels showed only
eak correlations with PCWP (Fig. 1). Inspection of each
catterplot revealed wide variations in PCWP for any given
alue of BNP and NT-proBNP. Both peptides also showed
eak but significant correlations with other central hemo-
ynamic parameters, troponin levels, and inverse correla-
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CI  cardiac index
eGFR  estimated glomerular filtration rate
ICU  intensive care unit
IQR  interquartile range
LV  left ventricular
LVEF  left ventricular ejection fraction
NT-proBNP  N-terminal pro-B-type natriuretic
peptide
PAC  pulmonary artery catheter
PCWP  pulmonary capillary wedge pressureions with LVEF and eGFR (Table 2). After adjusting for (CWP and LVEF, eGFR remained a significant indepen-
ent predictor of both BNP (beta coefficient 0.45, p 
.002) and NT-proBNP (beta coefficient 0.56, p 
.001). Body mass index, vasopressors, mechanical ventila-
ion, and hypoxemia (PO2/FiO2 ratio) did not affect natri-
retic peptide levels (data not shown).
Figure 2 demonstrates that natriuretic peptide levels were
pproximately four-fold higher in patients with impaired
ersus normal renal function, despite no differences in
CWP, cardiac index (CI), or LVEF. In addition, mean
all stress did not differ between the two groups (GFR60
l/min, 181 g/cm2 vs. GFR 60 ml/min, 175 g/cm2; p 
.20).
Figure 3 displays the correlations of BNP and NT-
roBNP to PCWP in the patients with normal and im-
aired renal function. For both peptides, the slope of the
egression lines increased, and the univariate correlations
ith PCWP strengthened in patients with an eGFR 60
l/min versus an eGFR 60 ml/min. A similar trend was
een in the correlations between the natriuretic peptide and
ulmonary artery pressure, CI, and LVEF when stratified
y renal function (Table 3). The interaction term for BNP
able 1. Clinical Characteristics and Hemodynamics of the
0 Patients
linical characteristics
Demographics
Age, yrs (median; IQR) 62 (52; 73)
Men 22 (55)
Women 18 (45)
White 28 (70)
Black 10 (25)
Other 2 (5)
Unit
Cardiac intensive care unit 17 (43)
Surgical intensive care unit 23 (57)
Diagnosis
Congestive heart failure 12 (30)
Sepsis or ARDS 12 (30)
Major abdominal surgery 9 (23)
Major vascular surgery 4 (10)
Trauma 3 (8)
Intubated/mechanically ventilated 26 (65)
Pressors/inotropes 15 (38)
Intra-aortic balloon pump 2 (5)
emodynamic parameters
Heart rate, beats/min 83 (76, 108)
RAP, mm Hg 10 (8, 13)
Mean PAP, mm Hg 29 (21, 35)
PCWP, mm Hg 14 (10, 22)
CO, l/min 5.9 (4, 8.3)
CI, l/min/m2 3.1 (2.1, 4.2)
SV, ml/beat 73 (48, 93)
Systemic vascular resistance, dyne · sec · cm5 923 (723, 1,635)
Ejection fraction, % 50 (20, 60)
linical characteristic data are expressed as number of patients (%). Hemodynamic
ata expressed as median (interquartile range).
ARDS  acute respiratory distress syndrome; CI  cardiac index; CO  carbon
onoxide; IQR  interquartile range; PAP  pulmonary artery pressure; PCWP 
ulmonary capillary wedge pressure; RAP  right atrial pressure; SV  stroke
olume.p  0.06) strongly suggests, and for NT-proBNP (p 
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f the relationship between the natriuretic peptides and
CWP.
ISCUSSION
he present study demonstrates that natriuretic peptide
evels were markedly elevated, but weakly correlated with
nvasive hemodynamics, most notably PCWP, in the setting
f critical illness. Regression analysis revealed that the
CWP varied widely at any given BNP and NT-proBNP
oncentration. Moreover, circulating concentrations of
NP and NT-proBNP were profoundly influenced by the
resence of renal failure, independent of pulmonary conges-
ion or depressed cardiac function. Thus, evidence from the
urrent study suggests that neither BNP nor NT-proBNP
re reliable markers of pulmonary congestion in critically ill
atients.
NPs and hemodynamics. The relatively weak correla-
ions between BNP and NT-proBNP and PCWP in the
urrent study are at odds with previous studies showing
trong correlations between these peptides and LV filling
ressures (4,5). However, in contrast to the current study,
revious studies have focused almost exclusively on patients
ith significant LV systolic dysfunction. This is an impor-
igure 1. Scatterplots showing the correlation between pulmonary capil-
ary wedge pressure (PCWP) and log B-type natriuretic peptide (BNP)
top) and log N-terminal pro-B-type natriuretic peptide (NT-proBNP)
bottom) in the overall cohort. Values in parentheses indicate raw BNP
nd NT-proBNP values.ant distinction, as BNP release occurs as a direct result of
p
aardiac stretch, not pressure, and thus is more closely
oupled to hemodynamics in the failing versus non-failing
eart (4,10–12). In addition, previous studies have excluded
ritically ill patients, thus minimizing the contributions of
otentially important non-mechanical stimuli for BNP
elease, such as neurohormonal activation and myocardial
schemia, both of which occur commonly in the setting of
ritical illness (13,14). Consistent with our results, a recent
tudy showed that BNP levels weakly correlated with
CWP (r  0.32, p  0.02) in a mixed ICU cohort, with
he optimal cutoff for BNP60% specific for a PCWP15
m Hg (15).
NPs and renal function. Previous studies have shown
hat natriuretic peptide levels correlate inversely with GFR
n chronic kidney disease (16,17). Investigators have postu-
ated that higher filling pressures and wall stress play an
mportant role in this cardiorenal link. However, in our
atients with renal failure (75% acute), natriuretic peptide
evels were massively elevated and could not be explained on
he basis of higher filling pressures, wall stress, or depressed
ardiac function. Moreover, natriuretic peptide levels
1,000 pg/ml (BNP) and 10,000 pg/ml (NT-proBNP)
ere more specific for a GFR 60 (BNP, 92%; NT-
roBNP, 100%) than for a PCWP 18 mm Hg (BNP,
2%; NT-proBNP, 60%).
To our knowledge, this study is the first to document
uch natriuretic peptide-hemodynamic dissociations in the
etting of renal failure and suggests that renal function has
more direct effect on circulating natriuretic peptide levels
han previously recognized. Moreover, the present study
ighlights the important limitations of these peptides as
emodynamic markers in this context. Further study is
arranted to determine what factors account for the in-
reased natriuretic peptide levels in renal failure (i.e., neu-
able 2. Univariate Correlations (r) of Log BNP and Log
T-proBNP With Hemodynamic and Other Parameters in the
verall Cohort (n  40)
Variable
BNP NT-proBNP
r p Value r p Value
AP 0.21 0.20 0.23 0.15
PAP 0.42 0.008 0.38 0.02
CWP 0.40 0.01 0.32 0.04
I 0.37 0.02 0.33 0.04
F 0.49 0.002 0.36 0.03
FR 0.35 0.03 0.45 0.004
ge 0.21 0.19 0.22 0.18
roponin I 0.33 0.04 0.43 0.006
V mass 0.31 0.10 0.13 0.52
VIDd 0.15 0.47 0.04 0.82
VIDs 0.23 0.26 0.13 0.50
NP  B-type natriuretic peptide; EF  ejection fraction; GFR  glomerular
ltration rate; LV  left ventricular; LVIDd  left ventricular diastolic diameter;
VIDs  left ventricular systolic diameter; mPAP  mean pulmonary artery
ressure; NT-proBNP  N-terminal pro-B-type natriuretic peptide; other abbrevi-
tions as in Table 1.
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ignificance of acute versus chronic kidney disease in this
aradigm.
tudy limitations. The relatively small sample size in our
tudy limited our ability to make more definitive conclusions
bout associations between the natriuretic peptide and
emodynamics and the modifying role of renal function.
his likely explains why the interaction term for BNP and
igure 2. Bar graphs showing B-type natriuretic peptide (BNP) and N-term
apillary wedge pressure (PCWP), cardiac index (CI), and ejection fraction
60 ml/min and an eGFR 60 ml/min. Median values are shown in bo
igure 3. Scatterplots showing the correlation between pulmonary capillary
-terminal pro-B-type natriuretic peptide (NT-proBNP) (B) in patients with an
nd an eGFR 60 ml/min (open squares).GFR fell just short of statistical significance in the PCWP
egression, despite evidence that renal function affects the
irculating levels and the hemodynamic associations of both
eptides. A potential methodologic limitation was the use of
he Cockcroft-Gault formula to estimate GFR, as opposed
o the Modification of Diet in Renal Disease formula for
stimation of GFR (13). However, eGFRs derived from
oth formulas were highly correlated in our dataset (r 
pro-B-type natriuretic peptide (NT-proBNP) values (top), and pulmonary
(bottom) in patients with an estimated glomerular filtration rate (eGFR)
th interquartile ranges shown in parentheses.
e pressure (PCWP) and log B-type natriuretic peptide (BNP) (A) and loginalwedg
estimated glomerular filtration rate (eGFR)60 ml/min (closed squares)
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ur results.
linical implications. The present study indicates that in
he setting of critical illness, BNP and NT-proBNP are not
eliable markers of circulatory congestion. This was espe-
ially true in patients with impaired renal function, as 75%
o 80% of the patients with a GFR60 ml/min would have
een inappropriately diuresed if standard cutoffs for BNP
nd NT-proBNP had been used to indicate pulmonary
ongestion. Thus, physicians should exercise caution in how
hey interpret elevated peptide concentrations in the ICU
etting, particularly in patients with renal failure.
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